Swipe om te navigeren naar een ander artikel
This study determined how the magnitude of change in positive subjective responses predicts clinical outcome in a treatment setting. Specifically, we attempted to define what constitutes a clinically important difference (CID) in subjective responses.
A 100-mm visual analog scale (VAS) measured subjective ratings of drug “high,” calculated via an anchor-based method with published data from participants receiving sustained-release naltrexone (NTX) and heroin in a laboratory setting. The data were then compared to clinical outcomes in a treatment trial with sustained-release naltrexone. A distribution-based method subsequently analyzed data from participants who received ALO-01 (extended-release morphine with sequestered NTX) to predict its abuse liability.
Differences in ratings of drug high of approximately 10 mm on a 100-mm line were clinically significant. By extrapolation, CIDs were also found between crushed or intact ALO-01 and immediate-release morphine sulfate (IRMS). No CIDs were found between intact and crushed ALO-01.
From laboratory and treatment trial data involving naltrexone, calculation of CIDs in subjective ratings of high is possible. Consequently, crushing/swallowing or injecting ALO-01 produces clinically significantly less drug high than oral or intravenous morphine alone, suggesting that ALO-01 has lower abuse liability by those routes than morphine formulations.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Kweder, S. L. (2006). Congressional testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources. Food and Drug Administration.
Department of Health and Human Services. (2009). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: draft guidance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed 25 Aug 2011.
Jones, J. B., Sokolowska, M., Setnik, B., Romach, M., Johnson, F., & Stauffer, J, et al. (2008). ALO-01, an investigational extended-release opioid formulation containing morphine sulfate and sequestered naltrexone: pharmacodynamic (drug liking) effects. Presented at 24th Annual meeting of the American Academy of Pain Medicine, Orlando, FL.
Webster, L., Jones, J. B., Johnson, F., Sekora, D., & Stauffer, J. (2008). Relative drug-liking/euphoria effects of intravenous morphine alone and in combination with naltrexone in recreational opioid users. Presented at 12th World Congress on Pain, Glasgow, Scotland.
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care,41, 582–592. PubMed
Stauffer, J., Setnik, B., Sokolowska, M., Romach, M., Johnson, F., & Sellers, E. (2009). Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: A randomized, double-blind, placebo-controlled, crossover study. Clinical Drug Investigation,29, 777–790. PubMedCrossRef
- Determining the clinically important difference in visual analog scale scores in abuse liability studies evaluating novel opioid formulations
Thomas A. Eaton
Sandra D. Comer
Dennis A. Revicki
Jeremiah J. Trudeau
Richard G. van Inwegen
Joseph W. Stauffer
Nathaniel P. Katz
- Springer Netherlands